Stocktoria
OSR Health, Inc. OSRH
OSR Health, Inc. (OSRH) earns a Piotroski F-score of 0/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 0/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.084 |
| Retained earnings / assets | -0.217 |
| EBIT / assets | -0.107 |
| Equity / liabilities | 2.874 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OSRH | OSR Health, Inc. | 0/9 | 1.04 | — | — |
| INBS | INTELLIGENT BIO SOLUTIONS INC. | 2/9 | — | — | — |
| USAQ | QHSLab, Inc. | 4/9 | -1.02 | — | — |
| AURX | Nuo Therapeutics, Inc. | 3/9 | — | — | — |
| FEMY | FEMASYS INC | 2/9 | — | — | — |
| TNON | Tenon Medical, Inc. | 4/9 | — | — | — |
| EBRCZ | EBR Systems, Inc. | 2/9 | -12.31 | — | — |
About OSR Health, Inc.
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026. OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.
FAQ
Is OSRH financially healthy?
OSR Health, Inc.'s Piotroski F-score is 0/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does OSRH pay a dividend?
No, OSR Health, Inc. does not currently pay a dividend.
What is the analyst price target for OSRH?
The average Wall-Street price target for OSR Health, Inc. is $10.00, about 3360.2% above the recent price, from 1 analysts.
Is OSRH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on OSR Health, Inc.: a Piotroski F-score of 0/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.